“The present circumstance has exposed some structural weaknesses in the EU’s medicines supply chain and a superior dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She advised that supply chain challenges be dealt with within an EU pharmaceutical system predicted to generally be launched by the tip